Theratechnologies Inc T.TH

NGM trial fail. A commercial decision???

[qwerty22]

This 25 min discussion is well worth listening to.
The suggestion is the trial didn't really fail clinically but NGM made a commercial decision because the company couldn't see a position for the drug in the market. Seems like a pretty brave decision for the company to make to pull the plug at that point.  It's worth listening to the end, it sounds compelling to me. 

https://surfingnash.com/s2-e28-special-episode-what-can-we-learn-the-aldafermin-discontinuation-in-f2-f3-nash/

So it shows what a negative impact this fail was for the whole NASH sector in terms of the reporting but if you accept this argument then clearly it shouldn't have been.

[SPCEO1]

A few points from this: 1.) Part of the reason for not going ahead was speculated to be because NGM's drug was an injectable versus MDGL's pill. That is certainly a concern for TH as well, but TH's pen should make using Egrifta it a bit more tolerable. 2.) I think Harrison said that even the same person reading the same biopsy result a second time came up with different readings! No

[qwerty22]

Red

[SPCEO1]

Great info - thanks! I suppose another reason for the delay on NASH, which  I guess you are alluding to, is they may have been in consultations with a NASH partner all this time and are working with them on the details of the protocol with the regulators. If all ends up in the right spot with the regulators, perhaps the potential partner will be happy to become an actual partner in NASH and